Biotechnology Reimbursement Law In Ukraine.

1. Introduction

Biotechnology Reimbursement Law in Ukraine concerns the legal framework governing the payment, compensation, and public financing of biotechnology-based medicines, biological products, advanced therapies, vaccines, genetic treatments, cell therapies, and other innovative medical technologies.

It addresses the circumstances in which the Ukrainian government, public healthcare institutions, health insurance arrangements, or other authorised funding mechanisms must pay for biotechnology-related healthcare services and products.

Unlike conventional pharmaceutical reimbursement, biotechnology reimbursement raises additional legal questions concerning:

High-cost biological and gene therapies.

Personalised medicine and genomic treatments.

Clinical evidence and therapeutic effectiveness.

Orphan medicinal products for rare diseases.

Biosimilars and biological medicines.

Public procurement and state-funded treatment.

Patient access to innovative medicines.

Reimbursement decisions and administrative appeals.

Pharmaceutical pricing and cost-effectiveness.

Cross-border procurement and international healthcare assistance.

The central legal challenge is balancing patients' rights to healthcare with public budget limitations, scientific uncertainty, pharmaceutical regulation, and equal access to innovative treatments.

Important distinction: Ukraine does not have one comprehensive statute specifically entitled the Biotechnology Reimbursement Law. Instead, reimbursement is governed by a combination of healthcare legislation, pharmaceutical legislation, public procurement rules, state financial guarantees, and regulations concerning medicines and medical products.

2. Constitutional and statutory framework

The principal legal sources are the following.

A. Constitution of Ukraine, Article 49

Article 49 guarantees the right to health protection, medical care, and medical insurance. It also establishes that state and communal healthcare institutions must provide medical care free of charge under the constitutional framework.

This provision is important for biotechnology reimbursement because patients may challenge the failure of public authorities to provide legally guaranteed medicines and treatment.

The Constitutional Court's interpretation in Judgment No. 10-rp/2002 is particularly relevant.

zakon.rada.gov.ua

 

B. Law No. 2168-VIII of 19 October 2017 — On State Financial Guarantees of Medical Care

This legislation establishes the State Programme of Medical Guarantees.

Its principal objectives include:

Defining publicly funded healthcare services.

Establishing state financial guarantees for patients.

Financing medicines and medical products through the state budget.

Establishing reimbursement mechanisms.

Regulating contractual relationships between the National Health Service of Ukraine (NHSU) and healthcare providers.

The programme provides the principal financial framework through which eligible medicines and medical products can receive public reimbursement.

CIS Legislation

 

C. Law No. 2801-XII — Fundamentals of Ukrainian Legislation on Healthcare

Article 54 is particularly relevant because it addresses the provision of medicines and immunobiological medicines free of charge or on preferential terms.

This is important for vaccines, biological preparations, and other immunobiological products.

The legislation also regulates the authorisation and handling of medicines by healthcare institutions.

zakon.rada.gov.ua

 

D. Cabinet of Ministers Resolution No. 854 of 28 July 2021

This is one of the most important regulatory instruments governing reimbursement.

It establishes procedures for reimbursing medicines and medical products under the State Programme of Medical Guarantees.

The framework covers:

Eligible registered medicines.

Eligible medical products.

Reimbursement lists and registers.

Price limitations.

Reimbursement arrangements.

Participation of pharmacies and healthcare institutions.

The resolution has undergone several amendments, so its applicable consolidated version must be checked when determining a patient's current entitlement.

on July 28, 2021 № 854+1

 

3. Meaning of reimbursement in biotechnology

Biotechnology reimbursement involves the payment of eligible costs associated with biotechnology-derived healthcare products and services.

Examples include:

Biotechnology categoryReimbursement issue
Monoclonal antibodiesPublic funding for biological medicines
Recombinant proteinsCoverage of specialised treatments
VaccinesPublic immunisation financing
BiosimilarsReimbursement and price competition
Gene therapiesFunding of expensive innovative treatments
Cell therapiesEligibility for specialised treatment financing
Orphan medicinesPublic provision for rare diseases
Genetic diagnosticsCoverage of medically necessary testing
Biotechnology medical devicesReimbursement under applicable programmes

An important legal distinction is that marketing authorisation does not automatically create a right to reimbursement.

A biotechnology medicine may be legally authorised for sale in Ukraine but remain outside the relevant reimbursement programme.

Similarly, an expensive innovative therapy may be funded through a separate state procurement or specialised healthcare programme rather than the ordinary outpatient reimbursement mechanism.

4. Health Technology Assessment (HTA) and biotechnology reimbursement

Health Technology Assessment is an important mechanism for deciding whether expensive biotechnology medicines should receive public funding.

Ukraine regulates state HTA through Cabinet of Ministers Resolution No. 1300 of 23 December 2020, as subsequently amended.

The State Expert Centre of the Ministry of Health performs the relevant assessment functions.

The assessment considers:

Clinical effectiveness: Whether the biotechnology treatment provides measurable therapeutic benefits.

Safety: Whether the treatment presents acceptable risks.

Economic evaluation: Whether the expected health benefits justify the financial expenditure.

Comparative effectiveness: Whether the new treatment performs better than existing alternatives.

Ethical considerations: Whether reimbursement promotes equitable access.

Social implications: Whether exclusion would disproportionately affect patients with rare diseases.

Budget impact: Whether the public healthcare system can sustainably finance the treatment.

Державний експертний центр МОЗ України+1

Recent development: March and July 2026

Ukraine updated its HTA framework in March 2026 through amendments to Resolution No. 1300, including alignment with European HTA developments. In July 2026, the State Expert Centre reported an updated methodological guideline incorporating assessment of additional clinical benefit.

Державний експертний центр МОЗ України+1

 

Legal significance: A biotechnology company seeking public reimbursement should prepare clinical evidence, comparative treatment data, economic analysis, and information about the expected patient population.

5. Reimbursement of biological medicines

Biological medicines are manufactured using biological sources or biological processes. They include monoclonal antibodies, recombinant proteins, hormones, immunological products, and other specialised therapies.

Their reimbursement raises particular regulatory challenges.

A. Monoclonal antibodies

Monoclonal antibodies are used in oncology, autoimmune diseases, and inflammatory disorders.

Reimbursement questions include:

Whether the medicine is included in the relevant public funding programme.

Whether the patient satisfies the clinical eligibility criteria.

Whether the prescribed treatment follows applicable clinical protocols.

Whether the medicine is supplied through centralised procurement or another public financing mechanism.

B. Recombinant proteins

Recombinant proteins are used in treating conditions such as growth hormone deficiencies, haemophilia, and certain metabolic disorders.

The government may provide these medicines through disease-specific programmes or other public procurement arrangements.

C. Biosimilars

Biosimilars are biological medicines highly similar to an already authorised reference biological medicine.

Their use can potentially reduce treatment costs and improve public access.

However, reimbursement decisions must take account of the medicine's regulatory authorisation, clinical suitability, applicable procurement rules, and the relevant reimbursement list.

D. Vaccines and immunobiological products

Vaccines are subject to public health and immunisation policies. Their financing may operate through national immunisation programmes and centralised procurement rather than ordinary outpatient reimbursement.

Article 54 of the Fundamentals of Ukrainian Healthcare Legislation provides an important statutory foundation for immunobiological medicines.

zakon.rada.gov.ua

 

6. Reimbursement of orphan biotechnology medicines

Orphan medicines are designed to prevent, diagnose, or treat rare diseases.

They are especially significant in biotechnology because many rare disorders require advanced biological or genetic treatments.

Examples include:

Enzyme replacement therapies.

Recombinant clotting factors.

Genetic disease treatments.

Specialised biological medicines.

Certain cell-based therapies.

Article 53-1 of the Fundamentals of Ukrainian Healthcare Legislation addresses state measures for preventing and treating rare diseases.

The statutory framework provides for uninterrupted and free provision of necessary medicines and specialised dietary products to eligible patients, according to applicable lists, quantities, and procedures.

Cabinet of Ministers Resolution No. 160 of 31 March 2015 establishes a procedure for providing medicines and specialised dietary products to people suffering from rare diseases.

This framework is particularly important when a patient cannot afford an expensive biotechnology medicine.

ipLex Судові рішення+1

7. National reimbursement procedure

The reimbursement framework generally involves several stages.

Regulatory authorisation

The biotechnology medicine must satisfy the applicable Ukrainian medicinal-product authorisation requirements, unless a specific statutory exception applies.

Clinical assessment

The relevant clinical evidence, treatment indications, safety, and effectiveness are examined.

Health technology assessment

Where required, the medicine undergoes state HTA to assess its clinical and economic value.

Reimbursement consideration

The medicine is considered for inclusion in the applicable public reimbursement list or a separate state-funded programme.

Pricing and budget assessment

Applicable price limits, financial requirements, and public funding arrangements are considered.

Prescription and dispensing

The patient obtains the medicine through the authorised healthcare and pharmacy arrangements applicable to the programme.

Payment and monitoring

Reimbursement is processed through the relevant state financing mechanism, with compliance and expenditure monitoring.

Resolution No. 854 is particularly relevant to medicines and medical products covered by the general reimbursement mechanism. Specialised biotechnology treatments may instead follow separate procurement and funding arrangements.

on July 28, 2021 № 854+1

 

8. Role of the National Health Service of Ukraine

The National Health Service of Ukraine (NHSU) plays a significant role in financing healthcare under the Programme of Medical Guarantees.

Its functions include:

Contracting with healthcare providers.

Purchasing publicly guaranteed healthcare services.

Administering relevant reimbursement arrangements.

Monitoring contractual performance.

Ensuring compliance with financing requirements.

The NHSU operates within the framework of the State Programme of Medical Guarantees.

An important distinction is that the NHSU does not independently guarantee reimbursement for every biotechnology medicine. Eligibility depends on the applicable statutory programme, reimbursement list, or specialised funding arrangement.

9. Public procurement of biotechnology medicines

Not every expensive biotechnology product is financed through ordinary pharmacy reimbursement.

Some medicines are purchased through centralised public procurement.

This is particularly relevant to:

Cancer biotechnology medicines.

Rare-disease treatments.

Biological medicines for children.

Immunobiological products.

Certain specialised genetic and metabolic treatments.

Public procurement introduces additional legal obligations.

These include:

Transparent procurement procedures.

Proper identification of medical needs.

Quality and regulatory compliance.

Prevention of conflicts of interest.

Contractual accountability.

Appropriate storage and distribution.

Financial auditing.

The procurement mechanism is important because a medicine may be legally available in Ukraine without being included in the ordinary reimbursement programme.

10. Patient rights and reimbursement disputes

Patients may face several forms of reimbursement-related disputes.

DisputeLegal issue
Medicine not suppliedFailure to fulfil a statutory obligation
Reimbursement refusedLegality of the refusal
Budget shortageResponsibility of the competent authority
Delayed procurementUnlawful administrative inaction
Rare-disease treatment deniedViolation of statutory patient entitlements
Medicine purchased privatelyClaim for recovery of expenses
Unequal accessEquality and non-discrimination concerns

A patient seeking reimbursement of privately incurred treatment costs should establish the relevant legal entitlement, the authority's failure to provide the medicine, the necessity of the purchase, and the amount of financial loss.

The Supreme Court has provided particularly important guidance on this issue.

11. Important judicial decisions and case laws

The following decisions are especially relevant to biotechnology reimbursement. Some concern general healthcare entitlements rather than biotechnology products specifically; their principles can nevertheless apply to biological and orphan medicines.

Case 1. Constitutional Court of Ukraine — No. 10-rp/2002, 29 May 2002

Constitutional precedent

Subject: Free medical care under Article 49 of the Constitution.

Facts and legal question:

The Constitutional Court considered the meaning of the constitutional guarantee that medical assistance in state and communal healthcare institutions must be provided free of charge.

Decision:

The Court interpreted the constitutional guarantee as requiring free medical care in state and communal healthcare institutions without prior, current, or subsequent payment by patients for that assistance.

It also explained that the scope of medical assistance and the legal arrangements for paid services must be regulated by law.

Relevance to biotechnology:

This decision establishes an important constitutional foundation for disputes involving publicly guaranteed biotechnology treatment.

For example, if an eligible patient is entitled to receive a biological medicine through a public healthcare programme, the state cannot simply disregard that entitlement by imposing an unlawful financial burden.

However, the judgment does not mean that every biotechnology medicine available on the market must automatically be publicly funded.

Constitutional Court of Ukraine+1

Case 2. Supreme Court — Case No. 761/29128/23, 5 March 2025

Directly relevant to reimbursement

Subject: Compensation for expenses incurred by a patient with a rare disease.

Facts:

The claimant suffered from acromegaly, a recognised rare disease.

The patient had to purchase medicines personally because the state failed to provide the necessary treatment free of charge.

The claimant sought reimbursement of the expenses incurred.

The first-instance court granted the claim, but the appellate court overturned that decision.

The dispute subsequently reached the Supreme Court.

Supreme Court's decision:

The Supreme Court's Civil Cassation Court restored the first-instance outcome.

It held that the state's failure to provide necessary medicines for a rare disease could create an obligation to compensate the patient's financial losses.

The Court emphasised:

The state's positive obligation to provide necessary medicines.

The patient's legitimate expectation of receiving legally guaranteed treatment.

The legal significance of previously established unlawful inaction.

The availability of compensation for property damage caused by unlawful conduct or omissions of public authorities.

Legal principle:

A patient who has been unlawfully deprived of medicines that the state is legally required to provide may claim compensation for the expenses incurred in purchasing those medicines.

Biotechnology relevance:

This is particularly important for expensive biotechnology treatments used in rare diseases, including enzyme replacement therapies and recombinant biological medicines, where patients may suffer substantial financial losses because of interrupted public supply.

court.gov.ua+1

Official judgment: Supreme Court decision, Case No. 761/29128/23.

12. Civil liability of public authorities

The Civil Code of Ukraine provides a legal basis for recovering property damage caused by unlawful actions or omissions of public authorities.

This is important in cases involving:

Failure to supply publicly funded biological medicines.

Unlawful refusal to provide rare-disease treatment.

Delayed provision of essential medicines.

Improper administration of healthcare funding.

Financial losses resulting from unlawful administrative decisions.

In appropriate circumstances, patients may pursue compensation against the responsible public authority.

The Supreme Court's 2025 judgment in Case No. 761/29128/23 demonstrates how these principles can operate in practice.

ipLex Судові рішення+1

 

13. International and European legal influence

Ukraine's biotechnology reimbursement system is influenced by international healthcare standards and its European integration commitments.

Important instruments and frameworks include:

A. European Convention on Human Rights

Article 2 protects the right to life, while Article 8 protects private and family life.

In exceptional circumstances, failures involving access to essential treatment may raise issues under these provisions, depending on the facts and the applicable Convention principles.

B. International Covenant on Economic, Social and Cultural Rights

Article 12 recognises the right to the highest attainable standard of physical and mental health.

It is relevant to state responsibilities concerning access to essential medicines and healthcare.

C. EU Health Technology Assessment Regulation 2021/2282

This regulation establishes a framework for cooperation in health technology assessment across EU Member States.

Ukraine's 2026 HTA reforms demonstrate efforts to align its assessment system with European approaches. However, EU reimbursement decisions do not automatically create reimbursement rights in Ukraine.

Державний експертний центр МОЗ України+1

 

14. Major legal challenges

Ukraine's biotechnology reimbursement framework faces several challenges.

ChallengeLegal significance
High treatment costsSustainability of public funding
Limited clinical evidenceDifficulty evaluating innovative therapies
Rare diseasesEnsuring uninterrupted treatment
Biosimilar competitionBalancing affordability and safety
Budget limitationsAllocation of public healthcare resources
Procurement delaysPatient access and administrative accountability
Regional inequalitiesEqual access to treatment
Personalised medicineAssessment of individualised therapies
Gene therapyLong-term effectiveness and financial uncertainty
Wartime disruptionContinuity of medicine supply

Particular concern: Gene therapy reimbursement

Gene therapies can involve a single treatment costing substantially more than conventional pharmaceutical treatment.

This creates difficult questions concerning:

Whether payment should be made upfront or in instalments.

Whether reimbursement should depend on long-term clinical outcomes.

Who bears financial responsibility if treatment fails.

How long-term patient monitoring should be financed.

Whether manufacturers should provide outcome-based payment agreements.

Ukraine's reimbursement framework must address these issues through appropriate financing, procurement, assessment, and contractual arrangements.

15. Legal remedies available to patients

A patient whose legally guaranteed biotechnology treatment has been denied may consider the following steps.

Obtain a specialist medical diagnosis and prescription.

Obtain written confirmation of the applicable treatment entitlement.

Request the medicine from the responsible healthcare institution or authority.

Preserve correspondence concerning non-supply or refusal.

Collect pharmacy invoices and proof of payment if the medicine was purchased privately.

Submit a complaint to the competent healthcare authority or NHSU, where appropriate.

Consider administrative or civil court proceedings depending on the nature of the dispute.

Seek compensation where the legal requirements for recovery of damages are established.

The appropriate defendant and court jurisdiction depend on whether the dispute concerns an administrative decision, a public authority's unlawful inaction, or a civil claim for compensation.

16. Recommendations for strengthening Ukrainian biotechnology reimbursement law

Several reforms could improve the system.

1. Specialised biotechnology reimbursement framework

Develop clearer reimbursement pathways for gene therapies, cell therapies, recombinant medicines, and advanced biological products.

2. Outcome-based reimbursement

Introduce appropriate payment arrangements linked to demonstrated treatment outcomes.

3. Rare-disease funding protection

Strengthen mechanisms for uninterrupted supply of essential orphan medicines.

4. Transparent HTA procedures

Publish clear assessment criteria, decisions, and reasons for reimbursement refusals.

5. Improved biosimilar access

Promote appropriate competition while maintaining biological medicine quality and patient safety.

6. Patient appeal mechanisms

Improve procedures for challenging reimbursement refusals and delays.

7. International cooperation

Develop cooperation with European healthcare institutions concerning clinical evidence, technology assessment, and medicine procurement.

17. Conclusion

Biotechnology Reimbursement Law in Ukraine is an evolving area of healthcare, pharmaceutical, constitutional, and administrative law.

Its legal structure is based principally on Article 49 of the Constitution, the Fundamentals of Ukrainian Legislation on Healthcare, Law No. 2168-VIII of 2017, Cabinet of Ministers Resolution No. 854 of 2021, and the regulatory framework governing health technology assessment.

Two judicial decisions are particularly important:

Constitutional Court Judgment No. 10-rp/2002: Establishes the constitutional interpretation of free medical care.

Supreme Court Case No. 761/29128/23 (2025): Recognises the possibility of compensation when the state unlawfully fails to provide free medicines for a rare disease.

Together, these legal principles provide important protection for patients requiring expensive biological and biotechnology-derived treatments.

Nevertheless, reimbursement is not automatic merely because a medicine is innovative, biologically derived, or authorised for marketing. The patient's entitlement depends on the relevant statutory funding programme, eligibility conditions, procurement arrangements, and applicable legal obligations.

The central legal principle is that public authorities must fulfil legally established healthcare entitlements, and unlawful failure to provide guaranteed medicines can give rise to judicial remedies and financial liability.

18. Important legal references

Legal authorityRelevance
Constitution, Article 49Right to healthcare
Law No. 2801-XII (1992)General healthcare framework
Article 53-1Rare-disease treatment
Article 54Medicines and immunobiological products
Law No. 2168-VIII (2017)State financial guarantees
Resolution No. 160 (2015)Rare-disease medicine provision
Resolution No. 1300 (2020)Health technology assessment
Resolution No. 854 (2021)Medicine and medical-product reimbursement
Judgment No. 10-rp/2002Constitutional free-medical-care interpretation
Case No. 761/29128/23 (2025)Compensation for failure to provide medicines

Primary research sources

Fundamentals of Ukrainian Legislation on Healthcare.

Cabinet Resolution No. 854.

State Expert Centre – Health Technology Assessment.

Constitutional Court decisions.

Supreme Court – Rare-disease medicine reimbursement judgment.

Academic note: The cases discussed above are verified Ukrainian healthcare precedents, not a claim that Ukrainian courts have already established a separate body of biotechnology-specific reimbursement jurisprudence.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT